Who owns Eton Pharmaceuticals, Inc. (AVEO)? Elite investor 13F holders

5 tracked elite investors reported holding Eton Pharmaceuticals, Inc as of 2026-06-30, including Cannell Capital, D.E. Shaw, Renaissance Technologies LLC, Polen Capital Management, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

5 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Cannell CapitalETON PHARMACEUTICALS INCSHARE2026-06-302026-08-18 00:00:006181041.00 USD170747.000000SharesreduceOriginal filing
D.E. ShawETON PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:006821962.00 USD188452.000000SharesbuyOriginal filing
Renaissance Technologies LLCETON PHARMACEUTICALS INCSHARE2026-06-302026-08-13 00:00:001893260.00 USD52300.000000SharesreduceOriginal filing
Polen Capital ManagementETON PHARMACEUTICALS INCSHARE2026-06-302026-08-04 00:00:001642720.00 USD45379.000000SharesaddOriginal filing
Gotham Asset ManagementETON PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:00578548.00 USD15982.000000SharesbuyOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown